219 related articles for article (PubMed ID: 20723210)
1. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
Wouters A; Pauwels B; Lardon F; Pattyn GG; Lambrechts HA; Baay M; Meijnders P; Vermorken JB
BMC Cancer; 2010 Aug; 10():441. PubMed ID: 20723210
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
4. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; De Paola F; Amadori D; Frassineti GL; Zoli W
Clin Cancer Res; 2002 Jan; 8(1):233-9. PubMed ID: 11801564
[TBL] [Abstract][Full Text] [Related]
5. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Monnerat C; Le Chevalier T
Ann Oncol; 2006 May; 17 Suppl 5():v86-90. PubMed ID: 16807472
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Adjei AA; Erlichman C; Sloan JA; Reid JM; Pitot HC; Goldberg RM; Peethambaram P; Atherton P; Hanson LJ; Alberts SR; Jett J
J Clin Oncol; 2000 Apr; 18(8):1748-57. PubMed ID: 10764436
[TBL] [Abstract][Full Text] [Related]
7. Clinical studies of pemetrexed and gemcitabine combinations.
Adjei AA
Ann Oncol; 2006 May; 17 Suppl 5():v29-32. PubMed ID: 16807459
[TBL] [Abstract][Full Text] [Related]
8. The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
Ngeow J; Toh CK
Curr Drug Targets; 2010 Jan; 11(1):61-6. PubMed ID: 19839926
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
Rodenbach M; Eyol E; Seelig MH; Berger MR
J Cancer Res Clin Oncol; 2005 May; 131(5):289-99. PubMed ID: 15657768
[TBL] [Abstract][Full Text] [Related]
10. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.
De Pas TM; Toffalorio F; Catania C; Noberasco C; Spitaleri G; Spaggiari L; De Braud F
Ann Oncol; 2009 Oct; 20(10):1747-8. PubMed ID: 19690055
[No Abstract] [Full Text] [Related]
12. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Ma CX; Nair S; Thomas S; Mandrekar SJ; Nikcevich DA; Rowland KM; Fitch TR; Windschitl HE; Hillman SL; Schild SE; Jett JR; Obasaju C; Adjei AA; ; ;
J Clin Oncol; 2005 Sep; 23(25):5929-37. PubMed ID: 16135464
[TBL] [Abstract][Full Text] [Related]
13. Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer.
Johnson D; Tonato M
Semin Oncol; 1999 Feb; 26(1 Suppl 4):1-2. PubMed ID: 10201514
[No Abstract] [Full Text] [Related]
14. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
Adjei AA
Lung Cancer; 2001 Dec; 34 Suppl 4():S103-5. PubMed ID: 11742712
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
18. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
West HL; Wakelee HA; Perry MC; Belt RJ; Chen R; Obasaju C
Ann Oncol; 2009 May; 20(5):850-6. PubMed ID: 19150937
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
